Used in pharmaceutical research as a potent inhibitor of tyrosine kinases, particularly targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). It shows promise in the development of anticancer agents due to its ability to block signaling pathways involved in tumor cell proliferation, survival, and metastasis. Demonstrates high selectivity and efficacy in preclinical studies against certain types of lung, breast, and colon cancers, especially those with specific EGFR mutations. Its structure allows for improved cellular permeability and target binding, making it a valuable scaffold in designing next-generation kinase inhibitors.